2020 ASCO Virtual Direct™ Highlights
W

2020 ASCO Update on Stage III Melanoma: Does Pembrolizumab Improve Recurrence-free Survival After Complete Resection of High-risk Disease?

By 2020 ASCO Virtual Direct™ Highlights FEATURING William Sharfman
By 2020 ASCO Virtual Direct™ Highlights FEATURING William Sharfman
63 views
July 17, 2020
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
12:46
Stanford Medicine

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Feat. A. Betof Warner
23:09
Total Health

Key Updates in Skin Melanoma

Feat. R. Seedor
06:39
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Final Analysis of Distant Metastasis-Free…

Feat. J. Luke
24:14
Masterclasses in Dermatology

Advances in the Treatment of Melanoma

Feat. D. Fisher
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
17:39
Melanoma Bridge 2023

Major Emerging Paradigm Shifts That Will Change Melanoma Management …

Feat. A. Eggermont
08:38
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "A Phase 3 Trial Comparing Fianlimab + Cem…

Feat. T. Panella
19:52
OncoAlert

Melanoma Updates: Adjuvant Therapy, Advanced Disease, Uveal Melanoma…

Feat. A. Betof Warner
08:46
Sapna Patel

Neoadjuvant Immunotherapy in the Treatment of Melanoma: What Do We K…

52:19
Winship Melanoma and Cutaneous Oncology Symposium

2024 Updates on Neoadjuvant Therapy for Resectable Melanoma

Feat. S. Patel
08:27
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Significant Durable Response With Fianlim…

Feat. O. Hamid
30:29
NYU Langone

Updates in Treatment with Immunotherapy for Melanoma and Related Mal…

Feat. J. Weber
20:55
2023 West Oncology Conference

2023 West Oncology Conference: Melanoma Updates

Feat. M. Mooradian
25:10
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024

Immunotherapy Combinations in Melanoma in 2024

Feat. J. Moyers
04:45
Sapna Patel

Optimal Duration of Neoadjuvant Treatment in Melanoma: What We Do No…

14:36
Melanoma Bridge 2023

Treating PD-1 Refractory Melanoma With TIL Therapy vs. Nivo+Ipi: Pro…

Feat. J. Smithy
16:00
AACR 2023 Conference Coverage

A Personalized Cancer Vaccine mRNA-4157 + Pembro vs. Pembro in Resec…

Feat. J. Weber
13:31
Melanoma Bridge 2023

What Is the Best Initial Treatment for Unresectable Mucosal Melanoma…

Feat. J. Luke
10:39
University of Colorado Department of Medicine

Cardio-Oncology: Definitions and Scope

Feat. L. Kondapalli
18:54
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Where Are We Going in Uveal, Mucosal & …

Feat. O. Hamid